Linde India is an interesting valuation thesis because the company is showing strong margin expansion and rising capital expenditure despite relatively modest top-line growth. At the same time, the stock is valued at nearly 97 times trailing earnings. The market is therefore not valuing Linde primarily on what it earns today. It is placing substantial value on the capacity, earnings and cash flows that could emerge over the next several years.
The question that this article poses is not simply whether industrial-gas demand will grow. It is whether Linde can convert that demand into enough volume growth, capacity utilisation, operating leverage and free cash flow to support the premium embedded in its share price.
With a Market capitalization of Rs.53,465.96 crore, the shares of Linde India closed on Monday at Rs.6,269.15, up 0.42% from its previous close of Rs.6,243.15. It trades at a P/E of 97.86x.
India’s industrial investment cycle is creating a broad demand pool
Industrial gases are unusual because they do not depend on one end market. Oxygen, nitrogen, argon and specialty gases are inputs into a wide range of industrial processes, meaning that Linde can benefit from several investment cycles at the same time.
Linde India estimated that the industrial-gases market could grow by around 7%, or approximately 1.5 times industrial production. The company identified steel, chemicals and energy, electronics, automotive, healthcare, defence, space and food and beverage as important demand pools through 2030. Its own estimates put growth in steel at 5% to 7%, chemicals and energy at 6% to 8%, electronics at 12% to 15%, automotive at 7% to 9%, healthcare at 10% to 12% and defence at 30% to 35%.
This is important because the industrial-gas opportunity is not dependent on one large capital-expenditure cycle continuing indefinitely. A slowdown in one customer segment can potentially be offset by growth elsewhere.
Steel remains a particularly important demand driver. Linde has long-term relationships with customers including Tata, SAIL and Jindal Stainless and has built more than 100 air-separation and nitrogen plants. It also operates plants on a build-own-operate basis for large industrial customers.
But the longer-term opportunity is increasingly moving beyond conventional steel and refining. Electronics and semiconductor manufacturing require high-purity gases and nitrogen. Solar manufacturing uses gases including nitrous oxide, silane and ammonia. Healthcare requires medical oxygen and other gases. Automotive production creates demand for nitrogen and argon, while defence applications include gases used in fabrication and controlled atmospheres.
That diversification is central to the Linde thesis. The company does not need every sector to grow at double-digit rates. What matters is that several end markets are expanding simultaneously and that Linde is positioned across them.
Industrial gases have an attractive combination of recurring demand and high infrastructure requirements
The industrial-gas business has two characteristics that distinguish it from many conventional manufacturing businesses. First, gases are often critical inputs rather than discretionary purchases. A steel plant, refinery, hospital or electronics manufacturer cannot simply stop using oxygen or nitrogen because the broader economy slows. Demand can fluctuate with production, but the product itself is embedded into the customer’s operating process.
Second, large onsite gas plants require substantial capital investment and technical expertise. Linde’s business includes the design, construction and operation of air-separation units and gas-distribution infrastructure.Linde has built more than 100 ASUs and nitrogen plants, including five 5,250 TPD ASUs at Jamnagar.
This creates a degree of customer stickiness. Once an industrial-gas supplier builds an onsite plant for a large customer, the relationship can extend over many years. Linde’s presentation specifically refers to long-term agreements with Tata, SAIL and Jindal Stainless and says it has more than 1,000 customers.
The sector also has a natural barrier to entry because competing for large onsite contracts requires engineering capabilities, reliability, distribution infrastructure and the ability to commit significant capital. However, this does not mean that industrial gases are automatically a high-growth business.
The distinction between industry growth and company growth matters. If the overall industrial-gas market grows 7%, Linde does not necessarily grow 7%. Its actual growth depends on market share, new contracts, customer capacity additions, pricing, utilisation and the mix between gases and project engineering. That distinction becomes particularly important at Linde’s valuation.
Linde’s position is stronger than its headline revenue growth suggests
Linde’s FY26 numbers provide an interesting contrast. Revenue Increased 1.82% to Rs.2,531 crore, largely because of lower project billing. Yet EBITDA increased 17.22% to Rs.976 crore, with the EBITDA margin rising from 33.51% to 38.58%. This is important because it shows that Linde’s earnings are not moving one-for-one with revenue. The company has two fundamentally different engines. The Gases division benefits from recurring demand, pricing discipline and capacity utilisation. The Project Engineering Division, or PED, is more project-driven and can therefore create greater volatility in revenue depending on project billing and execution.
FY26 demonstrated this clearly. Gas revenue grew 4.3%, while PED revenue fell 9.5%. Yet overall EBITDA still increased. This suggests that analysing Linde simply through consolidated revenue growth can miss an important part of the story.
The data also shows Linde with 18.2% ROCE and 13.7% ROE. The valuation is therefore being supported by a business with strong margins and capital efficiency, but not by exceptionally high historical revenue growth alone.
The biggest part of the thesis is what Linde does with its capex
This is where the investment case becomes more interesting. Linde generated approximately Rs.786 crore of operating cash flow in FY26. Its non-current assets increased 14.15%, while multiple projects were under construction.
This creates a very different framework for analysing the company. The important sequence is that capital expenditure creates new capacity, which then needs to achieve higher utilisation before it can translate into revenue, operating leverage and free cash flow.
A valuation model that simply treats higher capex as a permanent cash-flow drag can therefore miss the purpose of that expenditure. Conversely, assuming that every rupee of capex immediately creates earnings would also be too optimistic. There is usually a lag.
A new air-separation plant can require significant upfront capital, followed by a period during which volumes ramp up. Once utilisation rises, however, the incremental economics can become attractive because much of the infrastructure is already in place. This is why Linde’s future capacity utilisation may be more important than simply tracking the amount of capex announced.
The company has also been expanding into newer applications. Its presentation highlights solar and semiconductor gases and says it is working on indigenisation of these products. It also identifies healthcare, automotive and defence as important growth areas.
That gives Linde multiple avenues through which its current investments could eventually translate into higher earnings. But this is also the main risk to the valuation. If capacity additions come ahead of demand by too much, depreciation and capital employed can rise faster than revenue. That can produce exactly the opposite of the operating leverage investors are expecting.
The valuation is where the real debate begins
At approximately Rs.6,269.15 per share, Linde India has a market capitalisation of around Rs.53,465.96 crore and trades at approximately 97.86 times trailing earnings.That is a substantial premium to other listed Indian industrial-gas companies.
Stallion India Fluorochemicals is at about 51.41 times P/E, with a market capitalization of around Rs.2,675.77 crore and ROCE of 11.8%. Ellenbarrie Industrial Gases is another listed comparable. It supplies industrial and medical gases across eastern and southern India and operates across applications including medical, chemical, construction, defence and energy.
The comparison needs to be treated carefully. Linde is considerably larger, has a much broader customer base, possesses significant onsite infrastructure and has a long operating history with major industrial customers. But it does establish the scale of the premium. The market is effectively saying that Linde’s future earnings profile is materially different from that of a conventional industrial-gas company. The question is what exactly the market is paying for.
It appears to be paying for several things simultaneously. These include sustained industrial-gas demand growth, higher utilisation of newly created capacity, continued high gas margins, greater contribution from specialty gases, semiconductor and electronics exposure, healthcare growth, strong cash generation and Linde’s position with large industrial customers.
The valuation becomes easier to understand if the company is viewed as a long-duration compounder rather than a cyclical gas supplier. But that interpretation also raises the standard for future execution. At 97 times earnings, even strong earnings growth can take time to compress the multiple to a more conventional level.
For example, if earnings were to compound at 15% annually for five years, today’s 97 times P/E would mathematically fall to roughly 48 times on those future earnings, assuming the share price did not change. At 20% annual earnings growth, the multiple would fall to roughly 39 times after five years
That illustrates the central valuation issue. The company does not necessarily need explosive revenue growth. But it needs a combination of earnings growth and sustained profitability strong enough to allow today’s multiple to normalise without requiring the stock price to rise at the same pace.
What the market is pricing in
The most important takeaway is that Linde’s valuation cannot be justified purely by its current financials. FY26 revenue was only Rs.2,531 crore, while the company generated Rs.976 crore of EBITDA. The business has demonstrated impressive margin expansion, but historical revenue growth alone does not explain a 97.86 times P/E.
The valuation instead reflects expectations around the next stage of the business. Linde is spending today on capacity that can potentially support tomorrow’s volumes. Its customers are expanding across steel, automotive, electronics, healthcare, defence and other industrial applications. The company has a significant installed base and long-term customer relationships. Its gases business is producing strong margins, while project engineering provides an additional source of revenue and future customer relationships.
The market is therefore not simply buying today’s Rs.6,269.15 share price against today’s earnings. It is buying a view of what Linde’s earnings base could look like after the current investment cycle matures. That makes the most important variables over the next few years relatively clear.
Revenue growth is one of them. The question is whether the company can move from low-single-digit growth towards a more sustained mid- to high-single-digit trajectory. Capacity utilisation is another. The key question is whether new plants generate enough incremental volumes to justify the capital invested. Margins also matter.
Investors need to watch whether gas’s EBITDA margins can remain around the mid-30% range or improve further as utilisation increases. The product mix is another variable. Specialty gas, healthcare and electronics exposure could become large enough to change the company’s overall growth profile.
Cash flow will also be important. Operating cash generation needs to eventually outpace the investment required to support the next stage of capacity. Finally, there is the valuation itself. As earnings rise, the market may continue to assign a premium multiple, or the P/E may gradually normalise.